Roche Holdings AG Basel ADR Common Stock (RHHBY) Stock: What Does the Chart Say Monday?

Overall market sentiment has been high on Roche Holdings AG Basel ADR Common Stock (RHHBY) stock lately. RHHBY receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Roche Holdings AG Basel ADR Common Stock has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RHHBY!

See Full RHHBY Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RHHBY Stock Today?

Roche Holdings AG Basel ADR Common Stock (RHHBY) stock is trading at $31.85 as of 1:04 PM on Monday, Apr 1, a drop of -$0.07, or -0.22% from the previous closing price of $31.92. Volume today is 1,365,187 compared to average volume of 1,721,383. The stock has traded between $31.77 and $32.55 so far today. To see InvestorsObserver's Sentiment Score for Roche Holdings AG Basel ADR Common Stock click here.

More About Roche Holdings AG Basel ADR Common Stock

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. Click Here to get the full Stock Report for Roche Holdings AG Basel ADR Common Stock stock.